Daebonglsco Expects Pharma Monetization to Add to Growth in Cosmetic Materials
Predicted impact: Low
Daebonglsco대봉엘에스
078140 · KOSDAQ · ₩078140 · 대봉엘에스
₩6,550▼ ₩90 (1.36%)End-of-day · Oct 30, 2026 · End-of-day prices.
Price · 1Y −46.00%
- Market cap
- ₩73B
- Enterprise value
- ₩143B
- P/E
- 53.4×
- P/B
- 0.5×
- Dividend yield
- 0.8%
- ROE
- 1.0%
- Net margin
- 1.2%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−50.0% from the high
₩6,430Today: ₩6,430 – ₩6,630₩13,100
Returns
- 1W−3.7%
- 1M−14.4%
- 3M−14.3%
- 6M−39.8%
- YTD−43.8%
- 1Y−46.0%
- Volume today
- 12,240
- 0.8× the 20-day average
- Traded today
- ₩79M
- Listed shares
- 11,086,579
- EPS (12 months)
- ₩123
- Earnings yield 1.9%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 44 of 100 (50 is a normal day for this stock).
- SentimentPositiveNews: Headline points to expected growth from pharma monetization. Community: 0 bullish, 0 bearish posts this week.
- MomentumWeak-15.5% over the last month; the price is below its 20-day average.
- News impactLow1 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
Daebonglsco stock overview
Daebonglsco (대봉엘에스, KRX: 078140) is listed on KOSDAQ, in the Biotech & Pharma sector. The company, founded in 1986, develops and supplies pharmaceutical raw materials, such as ingredients for respiratory, hypertension and digestive treatments, and functional cosmetic ingredients made from natural and synthetic materials for customers in the medical beauty and bio sectors. Its shares closed at ₩6,550 on Oct 30, 2026, down 1.36% on the day, giving it a market value of ₩73B.
Key facts
- Market cap
- ₩73B
- Sector
- Biotech & Pharma
- Latest price change
- −1.36%
- As of
- Oct 30, 2026
- Main business
- The company, founded in 1986, develops and supplies pharmaceutical raw materials, such as ingredients for respiratory, hypertension and digestive treatments, and functional cosmetic ingredients made from natural and synthetic materials for customers in the medical beauty and bio sectors.
Quick answers about Daebonglsco
- What does Daebonglsco do?
- The company, founded in 1986, develops and supplies pharmaceutical raw materials, such as ingredients for respiratory, hypertension and digestive treatments, and functional cosmetic ingredients made from natural and synthetic materials for customers in the medical beauty and bio sectors. Its subsidiary PNK Skin Clinical Research Center provides human application testing, in vitro testing and big data consulting services for cosmetics, beauty devices and health functional foods. Its main customers are pharmaceutical and cosmetics companies, and sales are made directly, including export sales.
- What is the market cap of Daebonglsco?
- The market capitalisation of Daebonglsco was ₩73B at the close on Oct 30, 2026.
- Who are the largest shareholders of Daebonglsco?
- According to the latest official filings, the largest reported holders are Korea Securities Finance (4.09%, as of Jul 9, 2025); National Pension Service (2.30%, as of Dec 31, 2019); EMERGING MARKETS CORE EQUITY 2 PORTFOLIO (0.27%, as of Jul 31, 2026).
- When is the next earnings report from Daebonglsco?
- Korean companies rarely announce results dates in advance. Based on when Daebonglsco filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own Daebonglsco?
- Yes. The National Pension Service held 2.30% of Daebonglsco shares as of Dec 31, 2019.
Company profile
The company, founded in 1986, develops and supplies pharmaceutical raw materials, such as ingredients for respiratory, hypertension and digestive treatments, and functional cosmetic ingredients made from natural and synthetic materials for customers in the medical beauty and bio sectors. Its subsidiary PNK Skin Clinical Research Center provides human application testing, in vitro testing and big data consulting services for cosmetics, beauty devices and health functional foods. Its main customers are pharmaceutical and cosmetics companies, and sales are made directly, including export sales.
Written by AI from the company's latest annual report.
- Korean name
- 대봉엘에스
- Sector
- Biotech & Pharma
- CEO
- 박종호, 박진오
- Founded
- Jul 1986
- Listed
- Dec 2005
- Listed shares
- 11,086,579
- Fiscal year ends
- Month 12
- Website
- www.daebongls.co.kr
Similar companies
- Samsung Biologics207940 · ₩69T₩1,487,000+8.86%
- Celltrion068270 · ₩44T₩191,600+1.22%
- Alteogen196170 · ₩15T₩211,500−3.86%
- SK biopharmaceuticals326030 · ₩6.1T₩77,700−0.13%
- Yuhan000100 · ₩5.5T₩75,100+0.54%
- HLB028300 · ₩5.3T₩40,000+0.76%
- Hanmi Pharm128940 · ₩5.3T₩415,000+6.82%
- SAM Chun Dang Pharm000250 · ₩4.3T₩182,700−3.13%
Recent news
Recent filings
See all- Investor relations (IR) eventSep 21, 2026
- Half-year report (Jun 2026)Aug 14, 2026
- Other management mattersJul 6, 2026
- Quarterly report (Mar 2026)May 15, 2026
- Annual general meeting resultsMar 31, 2026
Titles in Korean until English translations are added.
Also known as: Daebonglsco / 대봉엘에스 / 078140 / KRX:078140
Source: KRX statistical information